KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

被引：0

作者：

Cunha Pereira, T. ^{[1
]}

Salgueiro, F. ^{[1
]}

Monteiro, A. ^{[1
]}

Felix Soares, R. ^{[1
]}

Macedo, F. ^{[1
]}

Jacinto, P. ^{[1
]}

Paulo, J. ^{[1
]}

Bonito, N. ^{[1
]}

Marques, M. ^{[1
]}

Ribeiro, J. ^{[1
]}

Sousa, G. ^{[1
]}

机构：

[1] Portuguese Oncol Inst Coimbra Francisco Gentil, Coimbra, Portugal

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-225

引用

页码：S163 / S164

页数：2

共 50 条

[21] EVALUATION OF CODON 12 AND 13 KRAS MUTATIONS AS BIOMARKERS OF RESPONSE TO PANITUMUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Peeters, Marc
Douillard, Jean-Yves
Van Cutsem, Eric
Salvatore, Siena
Zhang, Kathy
Williams, Richard
Wiezorek, Jeffrey
ANNALS OF ONCOLOGY, 2012, 23 : 27 - 28
[22] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
Dolinsky, J.
Salek, T.
Hlavata, Z.
Ivancova, H.
Risnyovszka, Z.
Mardiak, J.
Koza, I
ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
[23] Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience
Salek, T.
Mego, M.
Mardiak, J.
Andrasina, I.
Spanik, S.
Malec, V.
Barilla, R.
Riedelova, K.
Benedikty, A.
Dammak, A.
Porsok, S.
Svabova, V.
Chovanec, M.
Cipkova, A.
Usakova, V.
Siskova, M.
Jurisova, S.
Dolinsky, J.
Hlavata, Z.
Andrezalova, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[24] Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
Slaughter, Katrina N.
Thai, Theresa
Penaroza, Shayla
Benbrook, Doris M.
Thavathiru, Elangovan
Ding, Kai
Nelson, Tina
McMeekin, D. Scott
Moore, Kathleen N.
GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 11 - 15
[25] CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
S Matsusaka
S Cao
D L Hanna
Y Sunakawa
M Ueno
N Mizunuma
W Zhang
D Yang
Y Ning
S Stintzing
A Sebio
S Stremitzer
S Yamauchi
A Parekh
S Okazaki
M D Berger
R El-Khoueiry
A Mendez
W Ichikawa
F Loupakis
H-J Lenz
The Pharmacogenomics Journal, 2017, 17 : 543 - 550
[26] Comparative analysis of the Kohne, GERCOR and GEMCAD prognostic models in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab-based combination chemotherapy
Bruixola, G.
Diaz-Beveridge, R.
Melian, M.
Caballero, J.
Nino, O.
Escoin, C.
Akhoundova, D.
Salvador, C.
Segura, A.
Gimenez, A.
Aparicio, J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S376 - S377
[27] Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma
Usakova, V.
Sevcikova, K.
Usak, J.
Bartosova, Z.
Mikulova, M.
Spanik, S.
NEOPLASMA, 2013, 60 (01) : 83 - 91
[28] CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
Matsusaka, S.
Cao, S.
Hanna, D. L.
Sunakawa, Y.
Ueno, M.
Mizunuma, N.
Zhang, W.
Yang, D.
Ning, Y.
Stintzing, S.
Sebio, A.
Stremitzer, S.
Yamauchi, S.
Parekh, A.
Okazaki, S.
Berger, M. D.
El-Khoueiry, R.
Mendez, A.
Ichikawa, W.
Loupakis, F.
Lenz, H-J
PHARMACOGENOMICS JOURNAL, 2017, 17 (06): : 543 - 550
[29] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
Akun, E.
Okutur, K.
Seber, S.
Korkmaz, T.
Aydin, K.
Bozkurt, M.
Namal, E.
Hasbal, B.
Tecimer, C.
Demir, G.
JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
[30] Optimizing first-line chemotherapy for metastatic colorectal cancer
Adams, Richard A.
COLORECTAL CANCER, 2012, 1 (03) : 241 - 253

← 1 2 3 4 5 →